{"drugs":["Pyrazinamide"],"mono":{"0":{"id":"495110-s-0","title":"Generic Names","mono":"Pyrazinamide"},"1":{"id":"495110-s-1","title":"Dosing and Indications","sub":[{"id":"495110-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>HIV infection - Tuberculosis:<\/b> (40 to 55 kg) 1000 mg ORALLY once daily OR 1500 mg ORALLY 3 times a week OR 2000 mg ORALLY 2 times a week in combination with other antitubercular agents; twice-weekly dosing not recommended in HIV-patients with CD4 lymphocyte  counts less than 100 cells\/millimeter(3)<\/li><li><b>HIV infection - Tuberculosis:<\/b> (56 to 75 kg) 1500 mg ORALLY once daily OR 2500 mg ORALLY 3 times a week OR 3000 mg ORALLY 2 times a week in combination with other antitubercular agents; twice-weekly dosing not recommended in HIV-patients with CD4 lymphocyte  counts less than 100 cells\/millimeter(3)<\/li><li><b>HIV infection - Tuberculosis:<\/b> (76 to 90 kg) 2000 mg ORALLY once daily OR 3000 mg ORALLY 3 times a week OR 4000 mg ORALLY 2 times a week in combination with other antitubercular agents; twice-weekly dosing not recommended in HIV-patients with CD4 lymphocyte  counts less than 100 cells\/millimeter(3)<\/li><li><b>Tuberculosis:<\/b> (40 to 55 kg) 1000 mg ORALLY once daily OR 1500 mg ORALLY 3 times a week OR 2000 mg ORALLY 2 times a week in combination with other antitubercular agents<\/li><li><b>Tuberculosis:<\/b> (56 to 75 kg) 1500 mg ORALLY once daily OR 2500 mg ORALLY 3 times a week OR 3000 mg ORALLY 2 times a week in combination with other antitubercular agents<\/li><li><b>Tuberculosis:<\/b> (76 to 90 kg) 2000 mg ORALLY once daily OR 3000 mg ORALLY 3 times a week OR 4000 mg ORALLY 2 times a week in combination with other antitubercular agents<\/li><\/ul>"},{"id":"495110-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>HIV infection - Tuberculosis:<\/b> 15 to 30 mg\/kg ORALLY once daily (MAX, 2000 mg\/day) OR 50 mg\/kg ORALLY 2 times a week (MAX, 4000 mg\/day) in combination with other antitubercular  agents<\/li><li><b>Tuberculosis:<\/b> 15 to 30 mg\/kg ORALLY once daily (MAX, 2000 mg\/day) OR 50 mg\/kg ORALLY 2 times a week (MAX, 4000 mg\/day) in combination with other antitubercular  agents<\/li><\/ul>"},{"id":"495110-s-1-6","title":"Dose Adjustments","mono":"<ul><li>renal impairment (CrCl less than 30 mL\/min) 25 to 35 mg\/kg 3 times a week; alternatively, (CrCl 10 mL\/min or greater) usual dose of 25 to 30 mg\/kg every 24 hours OR (CrCl less than 10 mL\/min) 50% to 100% of usual dose every 24 hours<\/li><li><b>hemodialysis:<\/b> 25 to 35 mg\/kg 3 times a week after dialysis: alternatively, 25 to 30 mg\/kg after dialysis<\/li><\/ul>"},{"id":"495110-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>HIV infection - Tuberculosis<\/li><li>Tuberculosis<\/li><\/ul>"}]},"3":{"id":"495110-s-3","title":"Contraindications\/Warnings","sub":[{"id":"495110-s-3-9","title":"Contraindications","mono":"<ul><li>gout, acute<\/li><li>hepatic damage, severe<\/li><li>hypersensitivity to pyrazinamide<\/li><\/ul>"},{"id":"495110-s-3-10","title":"Precautions","mono":"<ul><li>diabetes mellitus; disease management may be more difficult<\/li><li>drug resistance, suspected; susceptibility tests recommended<\/li><li>hepatocellular damage; discontinue use and do not resume if signs occur<\/li><li>hyperuricemia with acute gouty arthritis; discontinue use and do not resume if signs occur<\/li><li>liver disease, preexisting, or increased risk of drug-related hepatitis (eg, alcohol abusers); monitoring recommended<\/li><\/ul>"},{"id":"495110-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B2 (AUS)<\/li><\/ul>"},{"id":"495110-s-3-12","title":"Breast Feeding","mono":"<ul><li>WHO: Compatible with breastfeeding.<\/li><li>Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},"4":{"id":"495110-s-4","title":"Drug Interactions","sub":{"1":{"id":"495110-s-4-14","title":"Major","mono":"<ul><li>Cyclosporine (theoretical)<\/li><li>Ethionamide (probable)<\/li><li>Rifampin (probable)<\/li><li>Zidovudine (probable)<\/li><\/ul>"}}},"5":{"id":"495110-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Endocrine metabolic:<\/b>Hyperuricemia<\/li><li><b>Gastrointestinal:<\/b>Nausea, Vomiting<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (40%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Anemia (rare)<\/li><li><b>Hepatic:<\/b>Hepatotoxicity<\/li><\/ul>"},"6":{"id":"495110-s-6","title":"Drug Name Info","sub":{"2":{"id":"495110-s-6-19","title":"Class","mono":"Antitubercular<br\/>"},"3":{"id":"495110-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"495110-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"495110-s-7","title":"Mechanism Of Action","mono":"Pyrazinamide, a nicotinamide analogue, is an antituberculous agent. Pyrazinamide may be bacteriostatic or bactericidal, depending on the concentration and the susceptibility of the organism, although the exact mechanism is unknown. It is active in vitro  at an acidic pH of 5.6 or less, similar to that found in early, active tubercular inflammatory lesions .<br\/>"},"8":{"id":"495110-s-8","title":"Pharmacokinetics","sub":[{"id":"495110-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 0.75 to 4 hours<\/li><li>Bioavailability, Oral: rapidly and almost completely absorbed<\/li><li>Effect of food: Cmax decreased by 17%, Tmax increased 80%<\/li><\/ul>"},{"id":"495110-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 0.75 to 1.65 L\/kg.<\/li><li>Protein binding: 5% to 10%<\/li><\/ul>"},{"id":"495110-s-8-25","title":"Metabolism","mono":"<ul><li>Liver: primary site via hydrolysis<\/li><li>Pyrazinoic acid: active<\/li><\/ul>"},{"id":"495110-s-8-26","title":"Excretion","mono":"<ul><li>Renal: approximately 70%, 1% to 14% unchanged<\/li><li>Dialyzable: yes (hemodialysis), 45% removed<\/li><\/ul>"},{"id":"495110-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Pyrazinamide: adults, 9 to 10 hours<\/li><li>Pyrazinamide: children (age 0.3 to 11 years), 6.7 hours<\/li><li>Pyrazinamide: cirrhosis, 15 hours<\/li><li>Pyrazinamide: end stage renal disease, 26 hours<\/li><li>Pyrazinoic acid: adults, 12.3 hours<\/li><li>Pyrazinoic acid: cirrhosis, 24 hours<\/li><\/ul>"}]},"10":{"id":"495110-s-10","title":"Monitoring","mono":"<ul><li>chest X-ray, sputum, symptomatic improvement<\/li><li>liver function tests, baseline and periodically during therapy<\/li><li>uric acid levels, baseline and periodically during therapy<\/li><\/ul>"},"11":{"id":"495110-s-11","title":"How Supplied","mono":"<b>Generic<\/b><br\/>Oral Tablet: 500 MG<br\/>"},"13":{"id":"495110-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause nausea, vomiting, or arthralgia.<\/li><li>Advise patient to report signs\/symptoms of hepatotoxicity or gout.<\/li><\/ul>"}}}